CTRI/2024/03/064135招募中3 期
A Phase 3, multicentre, open label, randomized, parallel group Study to Compare Efficacy,Safety and Immunogenicity of Biosimilar Recombinant Insulin Aspart Mix 30 (Manufactured by BioGenomics Limited) with NovoMix 30®(Manufactured by Novo Nordisk), in Diabetes Mellitus patients
BioGenomics Limited0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Type 2 DM patients willing to give written informed consent.
- •2. Type 2 DM patients who need insulin for their treatment and willing to take 1-3 injections daily.
- •3. Patients with T2DM, diagnosed since at least 6 months, who have been treated with premix human insulin or self-mixed human insulin with/without OADs (on stable dose for past 3 months).
- •4. HbA1c between 8.0% -10.0%, both inclusive.
- •5. Both sexes aged between 30 to 65 years, both inclusive.
- •6. Body Mass Index (BMI) =22kg/m2 and = 35 kg/m2, both inclusive.
- •7. Female patients who are not breastfeeding, and female patients of childbearing potential test negative for pregnancy, do not intend to become pregnant during the study, and agree to continue using a reliable method of birth control.
- •8. Willingness and ability to self-inject insulin, perform SMPG, and keep record in the patient diary.
排除标准
- •Patients who meet any of the following criteria will be excluded from the study:
- •1.Known or suspected hypersensitivity to insulin or related product(s).
- •2.Patients exclusively on OADs for management of diabetes mellitus.
- •3.Previous participation in this trial (participation is defined as randomization).
- •4.Patients on insulin analogs
- •5.Patients who have participated in an interventional medical, surgical, or pharmaceutical study within 30 days prior to screening or are likely to simultaneously participate in another therapeutic clinical study.
- •6.History of severe hypoglycemic or hyperglycemic episodes in the last 6 months before screening.
- •7.Patients on any immunosuppressive medication like glucocorticoids, tacrolimus, cyclosporine, methotrexate, rituximab.
- •8.History of hematological disorders which can affect HbA1c levels (hemoglobinopathies, hemolytic anemia)
- •9.History of any medical condition which in opinion of investigator may embarrass glycemic control findings.
- •10.Patients with any other clinically significant disease(s) which, in the opinion of the investigator could compromise the patient’s safety, the patient’s involvement in the study or overall interpretation of the trial data.
- •11.Cardiovascular disease such as stroke, unstable angina pectoris, myocardial infarction, coronary arterial bypass graft or angioplasty, congestive heart failure class III or IV as per New York Heart Association, within 6 months prior to screening
- •12.In case of impaired liver function, defined as alanine transaminase =2.5 times upper limit of normal
- •13.Patients with eGFR below 60mL/min
- •14.Patients who have less than 5 years of remission history from any malignancy (other than basal cell or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer).
- •15.Patients who are doubtful to comply with study procedures for mental, psychological or social reasons
- •16.Patients who have active proliferative retinopathy or macular edema
- •17.Known/screening seropositive patients of HIV or HBV or HCV
- •18.Women of child bearing potential who are not willing to follow a reliable and effective contraceptive measure during the course of the study and at least 1 week after the last visit
研究者
相似试验
未知
3 期
A phase 3 comparative study of TAP-144-SR(6M) in postoperative and hormone therapy-naive patients with premenopausal breast cancerPremenopausal breast cancerJPRN-jRCT2080221720TAKEDA PHARMACEUTICAL COMPANY LTD.164
招募中
1 期
A study to investigate the efficacy and safety of the lifileucel (LN-144, autologous tumorinfiltrating lymphocytes [TIL]) regimen plus pembrolizumab infusions compared with pembrolizumab infusions alone in participants with untreated, unresectable or metastatic melanomaMedDRA version: 21.1Level: LLTClassification code: 10053571Term: Melanoma Class: 10029104MelanomaCTIS2022-503140-41-00Iovance Biotherapeutics Inc.670
进行中（未招募）
1 期
A controlled study with Niraparib versus physician's choice in patients with previously-treated, HER2 negative, BRCA mutation-positive breast cancerHER2 negative, BRCA germline mutated breast cancerMedDRA version: 20.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-000684-85-PLTESARO Inc.306
进行中（未招募）
1 期
A controlled study with Niraparib versus physician's choice in patients with previously-treated, HER2 negative, BRCA mutation-positive breast cancerEUCTR2013-000684-85-GRTESARO Inc.306
已完成
3 期
A phase III, randomized, open label, multicenter, controlled trial of niraparib versus physician*s choice in previously-treated, HER2 negative, germline BRCA mutation-positive breast cancer;patientslobular carcinoma10006291breast cancerNL-OMON45039TESARO Inc.16